Drug intelligence / Profile preview

LBI-101

Development stage: Unknown
Lead developer: Longevity Biomedical
Modality: Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Injection

Overview

LBI-101 is an off-the-shelf allogenic tissue biomaterial developed as an injectable product for the permanent reconstruction of soft tissue affected by aging, traumatic injuries, and surgical procedures. The product is designed to stimulate tissue repair and regeneration. Clinical studies have demonstrated initial safety, biocompatibility, and new tissue formation without the scarring typically associated with other injection-based therapies. LBI-101 is currently being investigated in a Phase 2 clinical study for soft-tissue reconstruction[3][6][1].

Beyond the preview

Go deeper on LBI-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBI-101.

Explore the full profile